In Vitro and in Silico Evaluation of Some New 1H-Benzimidazoles Bearing Thiosemicarbazide and Triazole as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

References

• J. Domen, and I. Weissman, “Hematopoietic Stem Cells Need Two Signals to Prevent Apoptosis; BCL-2 Can Provide One of These, Kitl/c-Kit Signaling the Other,” The Journal of Experimental Medicine 192, no. 12 (2000): 1707–18.
   PubMed Web of Science ®Google Scholar
• A. Arora, E. M. P. Scholar, and E. Therapeutics, “Role of Tyrosine Kinase Inhibitors in Cancer Therapy,” The Journal of Pharmacology and Experimental Therapeutics 315, no. 3 (2005): 971–9.
   PubMed Web of Science ®Google Scholar
• C. Yewale, D. Baradia, I. Vhora, S. Patil, and A. Misra, “Epidermal Growth Factor Receptor Targeting in Cancer: A Review of Trends and Strategies,” Biomaterials 34, no. 34 (2013): 8690–707.
   PubMed Web of Science ®Google Scholar
• S. V. Sharma, D. W. Bell, J. Settleman, and D. A. Haber, “Epidermal Growth Factor Receptor Mutations in Lung Cancer,” Nature Reviews Cancer 7, no. 3 (2007): 169–81.
   PubMed Web of Science ®Google Scholar
• Y. Bansal, M. Kaur, and G. J. M. Bansal, “Antimicrobial Potential of Benzimidazole Derived Molecules,” Mini Reviews in Medicinal Chemistry 19, no. 8 (2019): 624–46.
   PubMed Web of Science ®Google Scholar
• J. Cheng, J. Xie, and X. Luo, “Synthesis and Antiviral Activity against Coxsackie Virus B3 of Some Novel Benzimidazole Derivatives,” Bioorganic & Medicinal Chemistry Letters 15, no. 2 (2005): 267–9.
   PubMed Web of Science ®Google Scholar
• J. Valdez, R. Cedillo, A. Hernández-Campos, L. Yépez, F. Hernández-Luis, G. Navarrete-Vázquez, A. Tapia, R. Cortés, M. Hernández, R. Castillo, et al. “Synthesis and Antiparasitic Activity of 1H-Benzimidazole Derivatives,” Bioorganic & Medicinal Chemistry Letters 12, no. 16 (2002): 2221–4.
   PubMed Web of Science ®Google Scholar
• K. C. Achar, K. M. Hosamani, and H. E Seetharamareddy, “In-Vivo Analgesic and anti-Inflammatory Activities of Newly Synthesized Benzimidazole Derivatives,” European Journal of Medicinal Chemistry 45, no. 5 (2010): 2048–54.
   PubMed Web of Science ®Google Scholar
• G. Ayhan‐Kılcıgil, C. Kus, E. D. Ozdamar, B. Can-Eke, and M. Iscan, “Synthesis and Antioxidant Capacities of Some New Benzimidazole Derivatives,” Archiv der Pharmazie (Weinheim) 340, no. 11 (2007): 607–11.
   PubMed Web of Science ®Google Scholar
• T. Iwahi, H. Satoh, M. Nakao, T. Iwasaki, T. Yamazaki, K. Kubo, T. Tamura, and A. Imada, “Lansoprazole, a Novel Benzimidazole Proton Pump Inhibitor, and Its Related Compounds Have Selective Activity against Helicobacter Pylori,” Antimicrobial Agents and Chemotherapy 35, no. 3 (1991): 490–6.
   PubMed Web of Science ®Google Scholar
• D. I. Shah, M. Sharma, Y. Bansal, G. Bansal, and M. Singh, “Angiotensin II-AT1 Receptor Antagonists: Design, Synthesis and Evaluation of Substituted Carboxamido Benzimidazole Derivatives,” European Journal of Medicinal Chemistry 43, no. 9 (2008): 1808–12.
   PubMed Web of Science ®Google Scholar
• Ş. Demirayak, U. A. Mohsen, and A. E. Karaburun, “Synthesis and Anticancer and anti-HIV Testing of Some Pyrazino [1, 2-a] Benzimidazole Derivatives,” European Journal of Medicinal Chemistry 37, no. 3 (2002): 255–60.
   PubMed Web of Science ®Google Scholar
• Z. Zhao, D. O. Arnaiz, B. Griedel, S. Sakata, J. L. Dallas, M. Whitlow, L. Trinh, J. Post, A. Liang, M. M. Morrissey, et al. “Design, Synthesis, and in Vitro Biological Activity of Benzimidazole Based Factor Xa Inhibitors,” Bioorganic & Medicinal Chemistry Letters 10, no. 9 (2000): 963–6.
   PubMed Web of Science ®Google Scholar
• H. A. Abdel‐Aziz, A. M. Gamal-Eldeen, N. A. Hamdy, and I. M. I. Fakhr, “Immunomodulatory and Anticancer Activities of Some Novel 2‐Substituted‐6‐Bromo‐3‐Methylthiazolo [3, 2‐a] Benzimidazole Derivatives,” Archiv der Pharmazie (Weinheim) 342, no. 4 (2009): 230–7.
   PubMed Web of Science ®Google Scholar
• B. Narasimhan, D. Sharma, and P. J. M. C. R. Kumar, “Benzimidazole: A Medicinally Important Heterocyclic Moiety,” Medicinal Chemistry Research 21, no. 3 (2012): 269–83.
   Web of Science ®Google Scholar
• D. Pathak, N. Siddiqui, B. Bhrigu, W. Ahsan, and M. S. Alam, “Benzimidazoles: A New Profile of Biological Activities,” Der Pharmacia Lettre 2, no. 2 (2010): 27–34.
   Google Scholar
• I. Khan, M. A. Tantray, H. Hamid, M. S. Alam, A. Kalam, and A. Dhulap, “Synthesis of Benzimidazole Based Thiadiazole and Carbohydrazide Conjugates as Glycogen Synthase Kinase-3β Inhibitors with Anti-Depressant Activity,” Bioorganic & Medicinal Chemistry Letters 26, no. 16 (2016): 4020–4.
   PubMed Web of Science ®Google Scholar
• C. S. Mizuno, A. G. Chittiboyina, F. H. Shah, A. Patny, T. W. Kurtz, H. A. Pershadsingh, R. C. Speth, V. T. Karamyan, P. B. Carvalho, M. A. Avery, et al. “Design, Synthesis, and Docking Studies of Novel Benzimidazoles for the Treatment of Metabolic Syndrome,” Journal of Medicinal Chemistry 53, no. 3 (2010): 1076–85.
   PubMed Web of Science ®Google Scholar
• R. V. Shingalapur, K. M. Hosamani, R. S. Keri, and M. H. Hugar, “Derivatives of Benzimidazole Pharmacophore: Synthesis, Anticonvulsant, Antidiabetic and DNA Cleavage Studies,” European Journal of Medicinal Chemistry 45, no. 5 (2010): 1753–9.
   PubMed Web of Science ®Google Scholar
• İ. Celik, G. Ayhan-Kılcıgil, B. Guven, Z. Kara, A. S. Gurkan-Alp, A. Karayel, and A. Onay-Besikci, “Design, Synthesis and Docking Studies of Benzimidazole Derivatives as Potential EGFR Inhibitors,” European Journal of Medicinal Chemistry 173, (2019): 240–9.
   PubMed Web of Science ®Google Scholar
• M. J. Akhtar, A. A. Khan, Z. Ali, R. P. Dewangan, M. Rafi, M. Q. Hassan, M. S. Akhtar, A. A. Siddiqui, S. Partap, S. Pasha, et al. “Synthesis of Stable Benzimidazole Derivatives Bearing Pyrazole as Anticancer and EGFR Receptor Inhibitors,” Bioorganic Chemistry 78, (2018): 158–69.
   PubMed Web of Science ®Google Scholar
• S. Demirel, G. Ayhan Kilcigil, Z. Kara, B. Güven, and A. Onay Beşikci, “Synthesis and Pharmacologic Evaluation of Some Benzimidazole Acetohydrazide Derivatives as EGFR Inhibitors,” Turkish Journal of Pharmaceutical Sciences 14, no. 3 (2017): 285–9.
   PubMed Web of Science ®Google Scholar
• B. Chu, F. Liu, L. Li, C. Ding, K. Chen, Q. Sun, Z. Shen, Y. Tan, C. Tan, Y. Jiang, et al. “A Benzimidazole Derivative Exhibiting Antitumor Activity Blocks EGFR and HER2 Activity and Upregulates DR5 in Breast Cancer Cells,” Cell Death & Disease 6, (2015): e1686.
   PubMed Web of Science ®Google Scholar
• Z. Piotrowska, and LVJJo Sequist, “Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors: A Review,” JAMA Oncol 2, no. 7 (2016): 948–54.
   PubMed Web of Science ®Google Scholar
• H. Zegzouti, J. Hennek, J. Alves, and S. Goueli, “ADP-Glo™ Kinase Profiling Systems for Targeted and Flexible Kinase Inhibitor Profiling,” (2014).
   Google Scholar
• R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin, and D. T. Mainz, “Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein − Ligand Complexes,” Journal of Medicinal Chemistry 49, no. 21 (2006): 6177–96.
   PubMed Web of Science ®Google Scholar
• R. Munnaluri, S. K. Sivan, and V. Manga, “Molecular Docking and MM/GBSA Integrated Protocol for Designing Small Molecule Inhibitors against HIV-1 gp41,” Medicinal Chemistry Research 24, no. 2 (2015): 829–41.
   Web of Science ®Google Scholar